AIM ImmunoTech Inc. (AIM), a biopharmaceutical company focused on immuno-oncology, on Wednesday provided an update on its Phase 1b/2 DURIPANC clinical trial evaluating the combination of Ampligen or rintatolimod and Imfinzi or durvalumab in treating late-stage pancreatic cancer.
Following a review of Phase 1 safety data, the Safety Committee has approved progression to Phase 2 of the study.
The data confirmed that the combination therapy was well-tolerated, with no severe treatment-related adverse events or dose-limiting toxicities.
Enrollment for the Phase 2 portion is set to begin imminently, with up to 25 patients expected to be enrolled.
Six Phase 1 patients will continue into Phase 2 as per the protocol.
The trial, which is taking place at Erasmus Medical Center in the Netherlands, is investigating the potential of combining Ampligen, an immune-modulator, with Imfinzi, an anti-PD-L1 immune checkpoint inhibitor, to treat metastatic pancreatic cancer.
AIM ImmunoTech remains optimistic about the potential of this combination therapy to address the high unmet need in late-stage pancreatic cancer.
Topline results from Phase 2 are anticipated in the future as the study progresses.
AIM closed Tuesday's (FEB.04 2025) trading at $0.18 down by 2.96%. In premarket trading Wednesday the stock is down at $0.18.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.